VAERS reports by lot

GSK DTaP/Tdap lot 97MR2: VAERS reports

25 VAERS reports list lot 97MR2 as a GSK DTaP/Tdap vaccine, received between 2023-06-29 and 2024-06-17. Data: VAERS public files through 31 December 2024 (site extract 2026-07-04).

Read this first. VAERS accepts reports from anyone, and a report does not establish that the vaccine caused the event. A lot's report count mostly reflects how many doses it contained, when it was used and who received it; no administered-dose counts are published for this lot, so counts are not rates and cannot rank lots against each other. Lot numbers in VAERS reports are typed by reporters and are sometimes wrong.
25
Reports
4%
Marked serious
0
With a death outcome
9
Months with reports

Symptom categories in these reports

A report can mention several categories, so the counts add up to more than the number of reports.

CategoryCount%
Neurological1928%
Injection-site / Local reaction1826%
Allergic / Anaphylactic710%
General / Systemic (non-local)69%
Gastrointestinal57%
Dermatological (non-injection-site)57%
Cardiac / Cardiovascular46%
Musculoskeletal34%
Autoimmune / Immune-mediated11%

Where reports came from

U.S. state of the reporter, where given (top 12).

Florida4
Michigan3
California2
Alabama2
Texas2
Illinois1
North Dakota1
Maryland1
New York1
Missouri1
Wisconsin1
Kansas1

Reports by month received

2023-061
2023-073
2023-083
2023-096
2023-101
2023-112
2023-121
2024-013
2024-065

Products recorded with this lot

Manufacturer and product as reported in VAERS. Reports listing the lot under more than one product are counted once.

Related

Source: VAERS public data (CDC/FDA), grouped by manufacturer and lot by the Open Source Medicine Foundation; extract 2026-07-04 16:35 UTC. Not medical advice. Report errors via contact.